ITONIS PHARMACEUTICALSItonis pharmaceuticals was created as a new division of Itonis, Inc. in collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam(R) Cold Remedy. This innovative pharmaceutical organization will produce and market prescription homeopathic preparations and over-the-counter products to treat chronic diseases and common ailments. The company will select products based on the speed to market seeking to bypass where appropriate the traditional and lengthy FDA approval process, while still maintaining the strictest levels of both safety and efficacy.
Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases. Press Release:
Charles Hensley, Ph.D., Inventor of Zicam« Cold Remedy, Creates Itonis Pharmaceuticals, a New Division of Itonis, Inc. IRVINE, CA--(Marketwire - Aug 16, 2012) - Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam´┐Ż Cold Remedy, are pleased to announce today the creation of a new organization that will produce and market over-the-counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. These preparations will be categorized as derivative pharmaceuticals in that while the preparations will be both safe and effective, the path to market is faster than traditional pharmaceutical drugs.
Dr. Hensley commented, "We had wide success upon creating the Zicam´┐Ż Cold Remedy and I believe that similar preparations can be created to treat many other common ailments. We plan to launch several products into this derivative pharmaceutical category over the coming months. It is exciting to be a part of this new venture and we plan to move expeditiously into the marketing of the formulations that we plan to announce."
Dr. Hensley has joined Itonis as President of its Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions.
Stock Quote - ITNS
Investor RelationsItonis Holdings Company is a trade name of Itonis Inc. (OTC:ITNS), a publicly traded company.
Contact our office at (949) 200-8887 or email us at firstname.lastname@example.org for more information.
Latest Quarterly Reporthttp://www.otcmarkets.com/financialReportViewer?symbol=ITNS&id=180805